Validation of Recombinant Heparan Sulphate Reagents for CNS Repair

Area of Science:

• Neuroscience
• Biochemistry
• Regenerative Medicine

Background:

• Central nervous system (CNS) diseases and injuries require therapies targeting multicellular pathology.
• Modified heparan sulphates (HS) are potent regulators of cellular processes and show potential for CNS repair.
• Current modified HS mimetics face supply chain challenges due to their origin from pharmaceutical heparin.

Purpose of the Study:

• To evaluate recombinant HS mimetics (rHS) produced via cellular synthesis as an alternative therapeutic source for CNS repair.
• To compare the efficacy of rHS with varying sulphation levels against a lead compound (LS-mHep7) in *in vitro* CNS injury models.

Main Methods:

• Manufacture of rHS reagents with controlled sulphation levels using mammalian cell multiplex genome engineering.
• *In vitro* validation of rHS efficacy using models mimicking CNS injury.
• Comparative analysis of low-sulphated rHS and highly sulphated rHS against LS-mHep7.

Main Results:

• Low-sulphated rHS compounds demonstrated efficacy in promoting remyelination and reducing astrocytosis, similar to LS-mHep7.
• Highly sulphated rHS compounds were found to stimulate neurite outgrowth.
• Cellular production of heparin mimetics offers a viable alternative source for potential CNS repair therapeutics.

Conclusions:

• Recombinant HS mimetics produced through cellular synthesis represent a promising and potentially scalable therapeutic strategy for CNS repair.
• Tailoring the sulphation degree of rHS allows for distinct therapeutic effects, such as promoting remyelination or neurite outgrowth.
• Cellular production overcomes the limitations of traditional heparin sourcing, paving the way for clinical applications in CNS regeneration.